title: [Transplant coronary artery disease--treatment with statins].
abstract: Hypercholesterolemia is a common disorder after heart transplantation and my be associated with the development of transplant coronary artery disease. 3-hydroxy 3-methylglutaryl coenzyme A reductase inhibitors (HMG CoA) are the most effective drugs to lower cholesterol level in transplant patients. However, interaction of immunosuppressants with HMG CoA inhibitors, which are metabolized by cytochrome P 450, increase incidence of skeletal muscle myopathy and rhabdomyolysis.
authors.affiliation: Klinika i Zakład Rehabilitacji Kardiologicznej i Elektrokardiologii Nieinwazyjnej Instytutu Kardiologii w Warszawie. jagienka@ikard.waw.pl
authors.forename: Jadwiga
authors.initials: J
authors.lastname: Wolszakiewicz
authors.forename: Maria
authors.initials: M
authors.lastname: Bilińska
mesh_terms: D003324:Coronary Artery Disease / Q000188:drug therapy* / Q000209:etiology; D016572:Cyclosporine / Q000009:adverse effects*; D003577:Cytochrome P-450 Enzyme System / Q000378:metabolism; D004347:Drug Interactions; D016027:Heart Transplantation / Q000009:adverse effects*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D006937:Hypercholesterolemia / Q000188:drug therapy* / Q000209:etiology; D012206:Rhabdomyolysis / Q000139:chemically induced*
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D016572:Cyclosporine; D003577:Cytochrome P-450 Enzyme System